Thin-wall hollow porous cystic-like graphitic carbon nitride with awakened n→π* electronic transitions and exceptional structural features for superior photocatalytic degradation of sulfamethoxazole.

Effective photoexcitation and carrier migration are the essential aspects to strengthen semiconductor-engaged redox reaction. Herein, a three-dimensional thin-wall hollow porous cystic-like g-CN (HPCN) with curved layer edge was successfully fabricated via a non-template thermal-condensation strategy. The construction of unique distorted structure can evoke the hard-to-activate n→π* electronic transition to some extent, broadening the absorption spectrum to 800 nm.

Construction of double-functionalized g-CN heterojunction structure via optimized charge transfer for the synergistically enhanced photocatalytic degradation of sulfonamides and HO production.

Herein, supporting g-CN embedded with benzene-ring (BCN) on P-modified g-CN (PCN) successfully synthesized the homogeneous photocatalyst BCN/PCN (PBCN) via a simple thermal polymerization reaction. Under blue-light (LED) irradiation, the optimized PBCN (0.448 min) demonstrated excellent photocatalytic performance, attaining over 74 times the degradation rate for sulfisoxazole (SSZ) in contrast to non-functionalized g-CN (CN, 0.

Efficient degradation of typical pharmaceuticals in water using a novel TiO/ONLH nano-photocatalyst under natural sunlight.

Photocatalytic degradation of typical pharmaceuticals in natural sunlight and in actual water is of great significance. In this study, the oxygen or nitrogen linked heptazine-base polymer (ONLH) was successfully incorporated with TiO nanoparticles and formed a TiO/ONLH nanocomposite which was responded to the natural sunlight. Under natural sunlight, the TiO/ONLH can effectively degrade ten types of pharmaceuticals.

Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine.

MenB-FHbp is a recombinant meningococcal serogroup B (MenB) vaccine composed of 2 factor H binding proteins (FHbps). Meningococcal vaccines targeting polysaccharide serogroup A, C, Y, and W capsules were licensed upon confirmation of bactericidal antibody induction after initial efficacy studies with serogroup A and C vaccines. Unlike meningococcal polysaccharide vaccines, wherein single strains demonstrated bactericidal antibodies per serogroup for each vaccine, MenB-FHbp required a more robust approach to demonstrate that bactericidal antibody induction could kill strains with diverse FHbp sequences.

A novel synthetic carbon and oxygen doped stalactite-like g-CN for broad-spectrum-driven indometacin degradation.

Achieving efficient solar utilization is a primary goal in the field of photocatalytic degradation of PPCPs. For this study, a broad-spectrum carbon and oxygen doped, porous g-CN (COCN) was synthesized via a simple co-pyrolysis of dicyandiamide and methylamine hydroiodide (CHN·HI). The 0.

Phosphate-modified m-BiO enhances the absorption and photocatalytic activities of sulfonamide: Mechanism, reactive species, and reactive sites.

Widespread usage of the sulfonamide class of antibiotics is causing increasing ecotoxicological concern, as they have the capacity to alter ambient ecosystems. Photocatalytic technology is an attractive yet challenging strategy for the degradation of antibiotics. For this work, the phosphate modification of m-BiO (BiO-P) was prepared via a one-step hydrothermal process involving sodium bismuthate and sodium phosphate, which was employed for the degradation of sulfamethazine (SMZ) under visible light irradiation.

Insights into the synergetic mechanism of a combined vis-RGO/TiO/peroxodisulfate system for the degradation of PPCPs: Kinetics, environmental factors and products.

In recent years, how to effectively remove emerging organic pollutants in water bodies has been studied extensively, especially in the actual complex water environment. In the present study, an effective wastewater treatment system that combined photocatalysis and an oxidizing agent was investigated. Specifically, visible-light driven reduced graphene oxide (RGO)/TiO composites were prepared, and peroxodisulfate (PDS) was used as electron acceptor to accelerate the photocatalytic activity of this material.

The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.

MenB-FHbp (Trumenba®; bivalent rLP2086) is a meningococcal serogroup B vaccine containing 2 variants of the recombinant lipidated factor H binding protein (FHbp) antigen. The expression of FHbp, an outer membrane protein, is not restricted to serogroup B strains of Neisseria meningitidis (MenB). This study investigated whether antibodies elicited by MenB-FHbp vaccination also protect against non-MenB strains.

[Targeted imaging ability of a biotinylated imaging probe Biotin-S-S-Rhodol for breast cancer cells in vitro].

Objective: To investigate performance of a biotinylated imaging probe 3a for targeted imaging of breast cancer cells.

Methods: Ultraviolet absorption spectrum and fluorescence spectrum were employed to analyze the spectral characteristics of 3a. The fluorescence spectrums of 3a treated with different concentrations of glutathione (GSH) were obtained to determine the sensibility of 3a to GSH.

Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.

Background: Bivalent rLP2086 (Trumenba), 1 of 2 meningococcal serogroup B (MnB) vaccines recently approved in the United States for the prevention of MnB disease in individuals 10-25 years of age, is composed of 2 lipidated factor H binding proteins from subfamilies A and B. This study evaluated the breadth of MnB strain coverage elicited by bivalent rLP2086 measured with serum bactericidal assays using human complement (hSBAs).

Methods: hSBA responses to diverse MnB clinical strains circulating in the United States and Europe (n = 23), as well as recent US university outbreak strains (n = 4), were evaluated.

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.

Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein sequences segregate into two distinct subfamilies, designated A and B. Here, we report the specificity and vaccine potential of mono- or bivalent fHBP-containing vaccines.

Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide.

The outer membrane protein LP2086, a human factor H binding protein, is undergoing clinical trials as a vaccine against invasive serogroup B meningococcal (MnB) disease. As LP2086 is a surface protein, expression of capsular polysaccharide could potentially limit accessibility of anti-LP2086 antibodies to LP2086 expressed on the surface of bacteria. To determine whether variability in expression levels of the serogroup B capsule (Cap B) might interfere with accessibility of anti-LP2086 antibody binding to LP2086, we evaluated the ability of anti-Cap B and anti-LP2086 antibodies to bind to the surface of 1263 invasive clinical MnB strains by flow cytometry.

Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele.

Cytomegalovirus (CMV) is a major threat in patients undergoing allogeneic bone marrow transplantation. The adoptive transfer of CMV-specific cytotoxic T lymphocytes (CTLs) expanded from the blood of CMV-seropositive donors has been shown to effectively control CMV infection. However, the requirement for safe and effective antigen-presenting cells (APCs) for each patient precludes broad applicability of this successful form of therapy.